RxDoctor Payments Data

Alan Verm, MD

Ophthalmology · Hendersonville, NCNPI 1558320382

Payments from drug & device makers

$1,727in general payments, 2019–2025

Across 73 payments — averaging $23.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$664
  • NEW World Medical,inc.$189
  • Tarsus Pharmaceuticals, Inc.$187
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$128
  • Ivantis, Inc$116
  • AbbVie$70
  • plus $373 from 15 others

What the payments were for

  • Food & beverage$1,727100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,727 in reported general payments places this provider in the 50th percentile of 588 ophthalmology providers in North Carolina.

See all ophthalmology providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,409,295
Medicare patients
2,217
Services billed
10,736

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine34$44,575
LumiganBimatoprost83$35,822
CombiganBrimonidine Tartrate/Timolol34$13,271
Latanoprost1,173$12,428
Prednisolone Acetate155$7,346
Travoprost41$6,826
Brimonidine Tartrate40$5,342
Alphagan PBrimonidine Tartrate14$3,712
MoxifloxacinMoxifloxacin Hcl163$3,477
Timolol Maleate190$2,005
Loteprednol Etabonate14$2,003
Doxycycline Hyclate32$1,521
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat96$1,452
Dorzolamide Hcl26$342
Ketorolac Tromethamine14$297

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$70$97,380165 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$128$2,00314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 588 ophthalmology providers in North Carolina.

Other ophthalmology in Hendersonville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →